{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:21:06Z","timestamp":1773832866788,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11255-020-02585-w","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T13:02:38Z","timestamp":1596805358000},"page":"291-299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications"],"prefix":"10.1007","volume":"53","author":[{"given":"Alejandrina M.","family":"Casta\u00f1eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Dutra-Rufato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Grosembacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Gonzalez-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-1130","authenticated-orcid":false,"given":"Carlos G.","family":"Musso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,7]]},"reference":[{"issue":"6 Suppl 1","key":"2585_CR1","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S1262-3636(14)72693-X","volume":"40","author":"S Halimi","year":"2014","unstructured":"Halimi S, Verg\u00e8s B (2014) Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 40(6 Suppl 1):S28\u2013S34. https:\/\/doi.org\/10.1016\/S1262-3636(14)72693-X","journal-title":"Diabetes Metab."},{"key":"2585_CR2","unstructured":"World Health Organization [Internet] (2018) https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes. Accessed 28 Aug 2018"},{"issue":"1","key":"2585_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/MNH.0000000000000084","volume":"24","author":"M \u0160krti\u0107","year":"2015","unstructured":"\u0160krti\u0107 M, Cherney D (2015) Sodium\u2013glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 24(1):96\u2013103","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"4","key":"2585_CR4","doi-asserted-by":"publisher","first-page":"588","DOI":"10.4103\/2230-8210.113725","volume":"17","author":"R Poudel","year":"2013","unstructured":"Poudel R (2013) Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition. Indian J Endocrinol Metab 17(4):588\u2013593","journal-title":"Indian J Endocrinol Metab"},{"issue":"2","key":"2585_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","volume":"27","author":"JE Gerich","year":"2010","unstructured":"Gerich JE (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27(2):136\u2013142","journal-title":"Diabet Med"},{"issue":"7","key":"2585_CR6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.2174\/138920011796504509","volume":"12","author":"T Salvatore","year":"2011","unstructured":"Salvatore T, Carbonara O, Cozzolino D, Torella R, Nasti R, Lascar N, Sasso FC (2011) Kidney in diabetes: from organ damage target to therapeutic target. Curr Drug Metab 12(7):658\u2013666. https:\/\/doi.org\/10.2174\/138920011796504509","journal-title":"Curr Drug Metab"},{"issue":"4","key":"2585_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2215\/CJN.06080616","volume":"12","author":"E Van Bommel","year":"2017","unstructured":"Van Bommel E, Muskiet M, Tonneijck L, Kramer M, Nieuwdorp M, van Raalte D (2017) SGLT2 Inhibition in the diabetic kidney\u2014from mechanisms to clinical outcome. Clin J Am Soc Nephrol. 12(4):700\u2013710","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"2585_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/MNH.0b013e32835a17ae","volume":"22","author":"MG Komala","year":"2013","unstructured":"Komala MG, Panchapakesan U, Pollock C, Mather A (2013) Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens 22(1):113\u2013119","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"2585_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/j.ajkd.2014.02.010","volume":"64","author":"L De Nicola","year":"2014","unstructured":"De Nicola L, Gabbai F, Liberti ME, Sagliocca A, Conte G, Minutolo R (2014) Sodium\/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis 64(1):16\u201324","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"2585_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S0025-7753(17)30625-5","volume":"147","author":"P G\u00f3mez-Fern\u00e1ndez","year":"2016","unstructured":"G\u00f3mez-Fern\u00e1ndez P, Fern\u00e1ndez-Garc\u00eda D (2016) Renal safety profile of sodium-glucose type 2 cotransporter inhibitors and other safety data. Med Clin (Barc). 147(Suppl 1):44\u201348. https:\/\/doi.org\/10.1016\/S0025-7753(17)30625-5","journal-title":"Med Clin (Barc)."},{"issue":"2","key":"2585_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2016","unstructured":"Vallon V, Thomson S (2016) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60(2):215\u2013225","journal-title":"Diabetologia"},{"issue":"8","key":"2585_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrendo.2011.243","volume":"8","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Solini A (2012) SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8(8):495\u2013502","journal-title":"Nat Rev Endocrinol"},{"issue":"S1","key":"2585_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0025-7753(17)30624-3","volume":"147","author":"A Tejedor-Jorge","year":"2016","unstructured":"Tejedor-Jorge A (2016) Implicaciones hemodin\u00e1micas y renales de los inhibidores del cotransportador sodio-glucosa tipo 2 en el contexto de la diabetes mellitus tipo 2. Med Cl\u00edn 147(S1):35\u201343. https:\/\/doi.org\/10.1016\/S0025-7753(17)30624-3","journal-title":"Med Cl\u00edn"},{"issue":"5","key":"2585_CR14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/MNH.0000000000000343","volume":"26","author":"H Rajasekeran","year":"2017","unstructured":"Rajasekeran H, Cherney D, Lovshin JA (2017) Do effects of sodium\u2013glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease? Curr Opin Nephrol Hypertens 26(5):358\u2013367","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"2585_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","volume":"26","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini E (2017) Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab 26(1):27\u201338","journal-title":"Cell Metab"},{"issue":"2","key":"2585_CR16","doi-asserted-by":"publisher","first-page":"e54442","DOI":"10.1371\/journal.pone.0054442","volume":"8","author":"U Panchapakesan","year":"2013","unstructured":"Panchapakesan U, Pegg K, Gross S, Komala M, Mudaliar H, Forbes J, Mather A (2013) Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One 8(2):e54442","journal-title":"PLoS One"},{"issue":"5","key":"2585_CR17","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jcjd.2014.05.006","volume":"38","author":"D Cherney","year":"2014","unstructured":"Cherney D, Perkins B (2014) Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection? Can J Diabetes. 38(5):356\u2013363","journal-title":"Can J Diabetes."},{"issue":"5","key":"2585_CR18","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.2337\/dc12-1503","volume":"36","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Veltkamp S, Smulders R, Kadokura T (2013) Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 36(5):1260\u20131265","journal-title":"Diabetes Care"},{"key":"2585_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.biopha.2017.07.095","volume":"94","author":"K Jaikumkao","year":"2017","unstructured":"Jaikumkao K, Pongchaidecha A, Chatsudthipong V, Chattipakorn S, Chattipakorn N, Lungkaphin A (2017) The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes. Biomed Pharmacother 94:176\u2013187","journal-title":"Biomed Pharmacother"},{"key":"2585_CR20","doi-asserted-by":"publisher","unstructured":"Osorio H, Coronel I, Arellano A, Pacheco U, Bautista R, Franco M, Escalante B (2012) Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxid Med Cell Longev 2012:542042. https:\/\/doi.org\/10.1155\/2012\/542042","DOI":"10.1155\/2012\/542042"},{"key":"2585_CR21","doi-asserted-by":"publisher","unstructured":"Wanner C (2017).EMPA-REG OUTCOME: the nephrologist\u2019s point of view. 120(1S):S59\u2013S67. https:\/\/doi.org\/10.1016\/j.amjcard.2017.05.012","DOI":"10.1016\/j.amjcard.2017.05.012"},{"issue":"1","key":"2585_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","volume":"94","author":"H Heerspink","year":"2018","unstructured":"Heerspink H, Kosiborod M, Inzucchi S, Cherney D (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 94(1):26\u201339","journal-title":"Kidney Int"},{"issue":"3","key":"2585_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/jcph.1030","volume":"58","author":"JA Brady","year":"2018","unstructured":"Brady JA, Hallow KM (2018) Model-based evaluation of proximal sodium reabsorption through SGLT2 in health and diabetes and the effect of inhibition with canagliflozin. J Clin Pharmacol. 58(3):377\u2013385. https:\/\/doi.org\/10.1002\/jcph.1030","journal-title":"J Clin Pharmacol."},{"issue":"5","key":"2585_CR24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/dmrr.2407","volume":"29","author":"S Maeda","year":"2013","unstructured":"Maeda S, Matsui T, Takeuchi M, Yamagishi S (2013) Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes\/Metab Res Rev 29(5):406\u2013412","journal-title":"Diabetes\/Metab Res Rev"},{"issue":"3","key":"2585_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jcjd.2017.06.008","volume":"42","author":"R Goldenberg","year":"2018","unstructured":"Goldenberg R, Berall M, Chan C, Cherney D, Lovshin J, McFarlane P, Weinstein J (2018) Managing the course of kidney disease in adults with type 2 diabetes: from the old to the new. Can J Diabetes 42(3):325\u2013334","journal-title":"Can J Diabetes"},{"issue":"9","key":"2585_CR26","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1007\/s00125-016-4008-2","volume":"59","author":"D Cherney","year":"2016","unstructured":"Cherney D, Lund S, Perkins B, Groop P, Cooper M, Kaspers S, von Eynatten M (2016) The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 59(9):1860\u20131870","journal-title":"Diabetologia"},{"key":"2585_CR27","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle H, Broedl UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 373:2117\u20132128","journal-title":"N Engl J Med."},{"issue":"24","key":"2585_CR28","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMe1904740","volume":"380","author":"J Ingelfinger","year":"2019","unstructured":"Ingelfinger J, Rosen C (2019) Clinical credence\u2014SGLT2 inhibitors, diabetes, and chronic kidney disease. N Engl J Med 380(24):2371\u20132373. https:\/\/doi.org\/10.1056\/NEJMe1904740","journal-title":"N Engl J Med"},{"key":"2585_CR29","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMc1712572","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews D, Phil D (2017) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 377:2097\u20132099. https:\/\/doi.org\/10.1056\/NEJMc1712572","journal-title":"N Engl J Med"},{"key":"2585_CR30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/nejmoa1812389","volume":"380","author":"S Wiviott","year":"2019","unstructured":"Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A, Silverman M, Zelniker T, Kuder J, Murphy S, Bhatt D, Leiter L, McGuire D, Wilding J, Ruff C, Gause-Nilsson I, Fredriksson M, Johansson P, Langkilde A, Sabatine M (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347\u2013357. https:\/\/doi.org\/10.1056\/nejmoa1812389","journal-title":"N Engl J Med"},{"key":"2585_CR31","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","volume":"10","author":"V Vallon","year":"1999","unstructured":"Vallon V, Richter K, Blantz RC, Thomson S, Osswald H (1999) Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10:2569\u20132576","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2585_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","volume":"44","author":"F Bonnet","year":"2018","unstructured":"Bonnet F, Scheen AJ (2018) Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 44(6):457\u2013464. https:\/\/doi.org\/10.1016\/j.diabet.2018.09.005","journal-title":"Diabetes Metab."},{"key":"2585_CR33","doi-asserted-by":"publisher","unstructured":"Prattichizzo F, De Nigris V, Micheloni S, Sala L, Ceriello A Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component. Diabetes Obes Metab 20(11): 2515\u20132522. https:\/\/doi.org\/10.1111\/dom.13488","DOI":"10.1111\/dom.13488"},{"key":"2585_CR34","volume-title":"The renal drug handbook","author":"C Ashley","year":"2019","unstructured":"Ashley C, Dunleavy A, Cunningham J (2019) The renal drug handbook. Taylor & Francis Group, New York"},{"issue":"3","key":"2585_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40264-017-0602-6","volume":"41","author":"A Szalat","year":"2017","unstructured":"Szalat A, Perlman A, Muszkat M, Khamaisi M, Abassi Z, Heyman S (2017) Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf 41(3):239\u2013252","journal-title":"Drug Saf"},{"issue":"24","key":"2585_CR36","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med."},{"issue":"2","key":"2585_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/2047487319880040","volume":"26","author":"F Prattichizzo","year":"2019","unstructured":"Prattichizzo F, La Sala L, Ryd\u00e9n L, Marx N, Ferrini M, Valensi P, Ceriello A (2019) Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. Eur J Prev Cardiol 26(2):73\u201380. https:\/\/doi.org\/10.1177\/2047487319880040","journal-title":"Eur J Prev Cardiol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02585-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-020-02585-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02585-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T23:20:41Z","timestamp":1628292041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-020-02585-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["2585"],"URL":"https:\/\/doi.org\/10.1007\/s11255-020-02585-w","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,7]]},"assertion":[{"value":"18 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}